论文部分内容阅读
目的:观察贝那普利对早期糖尿病肾病的临床疗效。方法:对符合糖尿病肾病诊断标准的32例患者给予贝那普利治疗,治疗期间原降糖治疗不变。测定治疗前后血压、空腹血糖、血肌酐及24h尿白蛋白排泄量。结果:32例患者治疗前后的血压、尿白蛋白排泄量比较,差异有统计学意义(P<0.05);空腹血糖、SCr比较,差异无统计学意义(P>0.05)。所有患者用药前后肝、肾功能无明显变化。结论:贝那普利能减少血管紧张素Ⅱ的生成,抑制细胞因子包括TGF-β的上调,改善肾小球毛细血管的通透性,减少细胞外间质如Ⅳ型胶原的积聚及瘢痕形成,对糖尿病肾病蛋白尿及肾功能的进展有明显的减缓作用。
Objective: To observe the clinical efficacy of benazepril on early diabetic nephropathy. Methods: 32 patients who meet the diagnostic criteria of diabetic nephropathy were treated with benazepril, while the treatment of the original hypoglycemic treatment remained unchanged. Blood pressure, fasting blood glucose, serum creatinine and urinary albumin excretion were measured before and after treatment. Results: There were significant differences in blood pressure and urinary albumin excretion before and after treatment in 32 patients (P <0.05). There was no significant difference in fasting blood glucose and SCr between the two groups (P> 0.05). All patients before and after treatment of liver, kidney function no significant change. CONCLUSION: Benalipril can reduce the production of angiotensin Ⅱ, inhibit the up-regulation of cytokines including TGF-β, improve the glomerular capillary permeability and reduce the accumulation of extracellular matrix such as type Ⅳ collagen and scar formation , On the diabetic nephropathy proteinuria and renal function has a significant slowdown in the role of progress.